• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Reported Monday June 10, 2024 "Amneal, U.S. FTC Win Order Removing Teva Inhaler Patents From FDA List" - Reuters News

    6/11/24 10:40:07 AM ET
    $AMRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email

    https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/

     

    Drugmaker Amneal Pharmaceuticals (AMRX.O), opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical (TEVA.TA), opens new tab patents from a U.S. Food and Drug Administration list of patents covering Teva's breathing drug ProAir HFA.

    U.S. District Judge Stanley Chesler agreed with Amneal and the FTC, opens new tab that Teva's patents only covered inhaler device technology, ordering it to remove the listings from the FDA's Orange Book and clearing an obstacle for Amneal's proposed generic.

    The decision follows the FTC's warnings to drugmakers including Teva over the misuse of Orange Book patent listings to wrongly extend patent monopolies on brand-name drugs. Chesler on Monday also rejected Teva's bid to dismiss Amneal's allegations that Teva violated state and federal antitrust law.

    Spokespeople for Teva, Amneal and the FTC did not immediately respond to requests for comment on the decision.

    Teva sued Amneal for patent infringement last year based on its proposed generic version of ProAir HFA, which treats bronchial spasms caused by diseases like asthma. Teva stopped making ProAir HFA in 2022.

    Amneal counterclaimed that Teva had improperly submitted the patents to the Orange Book, which lists patents that cover drugs that the FDA has deemed safe and effective.

    The FTC last year sent notices to Teva and other drugmakers disputing 110 of their Orange Book patents, and said the companies may have improperly submitted them to the FDA to delay generic competition. The commission filed a brief supporting Amneal in the New Jersey case.

    Chesler agreed with Amneal and the FTC that Teva's patents only cover parts of a "metered inhaler device" and "do not claim or even mention" ProAir HFA.

    The case is Teva Branded Pharmaceutical Products R&D Inc v. Amneal Pharmaceuticals of New York LLC, U.S. District Court for the District of New Jersey, No. 2:23-cv-20964.

    Get the next $AMRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRX
    $TEVA

    CompanyDatePrice TargetRatingAnalyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/9/2025$35.00Overweight
    Barclays
    Amneal Pharmaceuticals Inc.
    $AMRX
    12/9/2025$15.00Overweight
    Barclays
    Teva Pharmaceutical Industries Limited
    $TEVA
    12/5/2025$35.00Sector Outperform
    Scotiabank
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Amneal Pharmaceuticals Inc.
    $AMRX
    6/6/2025$12.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    Amneal Pharmaceuticals Inc.
    $AMRX
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    More analyst ratings

    $AMRX
    $TEVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amneal Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    3/26/26 3:43:45 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.

    DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    3/25/26 4:16:09 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Amneal Pharmaceuticals Inc.

    DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    3/25/26 4:15:42 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Teva Pharma with a new price target

    Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00

    12/9/25 8:54:12 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Amneal Pharmaceuticals with a new price target

    Barclays initiated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:42:32 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Teva Pharma with a new price target

    Scotiabank initiated coverage of Teva Pharma with a rating of Sector Outperform and set a new price target of $35.00

    12/5/25 8:41:58 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AMRX
    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

    Teva's biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva's proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA.These milestones demonstrate Teva's biosimilars expertise and are a significant step in Teva's Pivot to Growth strategy, highlighting its transformation into a leading biopharmaceutical company with a broad biosimilars portfolio. TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfo

    3/30/26 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Releases Q1 2026 Aide Memoire

    TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

    TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Patel Chintu

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:20:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Patel Chirag K.

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:19:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sabag Mark

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/19/26 4:01:11 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Financials

    Live finance-specific insights

    View All

    Teva Releases Q1 2026 Aide Memoire

    TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

    TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

    ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.0

    2/27/26 6:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Leadership Updates

    Live Leadership Updates

    View All

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

    First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech

    11/19/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

    SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    11/14/24 4:11:34 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    10/31/24 6:51:29 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care